GeneDx Holdings Corp. (WGS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $69.97, GeneDx Holdings Corp. (WGS) is priced for today's economics sustained for ~7.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/WGS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 12.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.7 years.

Reconcile: at the x-ray's 9.3% required return this reads ~10.9%/yr; the models below use their own rates.

How unusual the bet is: within-range

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=6)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• The single number that decides GeneDx is reimbursement per test: exome and genome volume surged 34% to 27,488 tests in the first quarter, but the blended average reimbursement rate came in near $3,300, about $200 below plan, which is why the company cut full-year revenue guidance even as volume soared.
• The biggest risk is that this is a company still spending more than it earns: the operating result is negative and the business is funding growth from a modest cash balance, so the path to the promised profitability is the whole bet.
• What to watch is the volume-versus-rate tug of war: management lowered 2026 revenue guidance to $475 to $490 million while still targeting at least 30% exome and genome volume growth, roughly 70% adjusted gross margin, and positive adjusted net income.

Bull Case

The decisive metric for GeneDx is test volume, and it is growing fast. Exome and genome test volume rose 34% year over year to 27,488 results in the first quarter, and the revenue from those tests grew 27% to $90.6 million. For a diagnostics company, volume is the leading indicator of everything: it reflects clinician adoption, it builds the dataset that makes the tests more valuable over time, and it eventually scales into operating leverage. GeneDx sits in one of the most compelling corners of medicine, using whole-exome and whole-genome sequencing to diagnose rare and undiagnosed genetic disease, an application where the clinical value is high and the addressable market is expanding as the technology becomes standard of care.

The unit economics already work at the gross-margin line, which is what separates a scalable diagnostics business from a perpetual money loser. Adjusted gross margin held at 69% and GAAP gross margin at 67% in the quarter. A genetic-testing company earning roughly 70 cents of gross profit on each revenue dollar has the structural margin to reach profitability if volume keeps climbing and the cost per test keeps falling with scale. Management is guiding to positive adjusted net income for the full year, which would mark the transition from a cash-burning growth story to a self-funding one. The growth methods that reach the price are pricing exactly that transition.

The bull case rests on the durability of the volume trajectory and the eventual normalization of reimbursement. The company's ability to grow revenue depends on increasing market penetration and obtaining contracted reimbursement coverage from third-party payors, and rising volume gives it negotiating leverage to broaden that coverage over time. With a clean balance sheet carrying net cash and no debt, the company can fund its growth without the refinancing risk that sinks many development-stage names. If GeneDx converts its 30%-plus volume growth into stable reimbursement and the promised profitability, the static valuation methods that look expensive today will have been measuring a business at the wrong point in its development.

Bear Case

The hard truth the first quarter exposed is that volume growth does not pay the bills if the price per test falls, and reimbursement is the variable GeneDx least controls. Volume jumped 34%, but the company still cut its full-year revenue guidance by 12% at the midpoint, to $475 to $490 million, because the blended average reimbursement rate came in near $3,300, about $200 below expectations, on product mix shifts and a lower parental sample mix. That is the central fragility of the entire business model laid bare: GeneDx can grow tests faster than ever and still miss revenue, because each test is worth only what a payor decides to pay for it. The company's own filings make the dependency explicit, warning that its ability to increase billable tests and revenue depends on achieving reimbursement from third-party payors. When a company's revenue can move materially on a payor's mix decision rather than its own execution, the forecast is inherently shaky.

The price-to-fundamentals gap is the bear's strongest arithmetic. The business runs at a negative operating margin, so the methods that value it on assets or current earnings power land far below the price, several at a fraction of it. Only the growth methods reach the price, and they do so by assuming the company hits the durable, profitable scale it is promising but has not yet demonstrated. The filings also flag a structural risk for a fast-growing, money-losing company: when revenue does not meet expectations, the company may not be able to cut spending promptly to match, which is exactly the squeeze a guidance cut creates. A miss on the top line with a fixed cost base widens the loss.

Dilution is the quiet cost the bull case understates. The share count has been growing rapidly, a reflection of how the company funds its growth, so even as the business scales, existing holders own a shrinking slice of it. A diagnostics company that needs continued investment to reach profitability, and that funds that investment partly with equity, asks its shareholders to keep paying for the growth they are betting on. The bull and the bear agree the volume growth is real and the gross margin is healthy. They disagree on whether the reimbursement uncertainty and the still-negative operating result justify a price that only the most optimistic growth scenario reaches, when the most recent quarter showed the reimbursement assumption breaking the wrong way.

Valuation

GeneDx is a growth-stage diagnostics company that is not yet profitable, so the price cannot be anchored on current earnings; it is anchored on the company reaching durable, profitable scale. At $58.95 (June 28, 2026) the price embeds an assumption that volume keeps compounding above 30% and that reimbursement and cost discipline carry the business to a sustainable operating margin over the next several years.

The method families sort the way they do for a pre-profit growth name. The asset-value methods land at a small fraction of the price, because there is little book value to anchor on and the company earns a negative operating margin today. The peer-multiple method, applying a sector revenue multiple, lands below the price as well. Only the growth methods, which project the volume trajectory and the eventual margin forward, reach the price. That is the signature of a durability premium: the static frames structurally cannot price a business whose value is entirely in its future scale, so only the forward methods support the quote. The honest read is that a buyer at this price is paying for the transition to profitability, not for anything the income statement shows today.

Solvency here is about runway, not leverage. The company carries net cash and no debt, which removes refinancing risk, but it is burning cash at the operating level, so the relevant question is how long the balance sheet funds the path to the positive adjusted net income management is targeting, and whether further equity issuance dilutes holders along the way. The decisive judgment for the value is not any single method's number; it is reimbursement. The first quarter showed that volume can grow 34% and revenue can still disappoint when the blended rate slips, so the entire thesis turns on whether GeneDx can stabilize and grow its average reimbursement per test while it scales. If it can, the growth methods are right. If reimbursement keeps surprising lower, the volume growth funds losses rather than profits, and the static methods are the more honest guide.

Catalysts

The first-quarter 2026 report in early May was the catalyst, and it was a tale of two numbers: surging volume and a guidance cut. Exome and genome volume grew 34% to 27,488 results and the related revenue grew 27% to $90.6 million, with total revenue up 17% to $102.3 million. But the company lowered full-year 2026 revenue guidance by about 12% at the midpoint, to $475 to $490 million, because the blended average reimbursement rate came in near $3,300, roughly $200 below plan, on product mix shifts and a lower parental sample mix. The company still targets at least 30% exome and genome volume growth, adjusted gross margin around 70%, and positive adjusted net income for the year.

The forward catalysts all run through reimbursement and the path to profitability. The blended average reimbursement rate is the single metric to watch each quarter, because volume growth has already proven it can outrun revenue when the rate slips. Progress on contracted coverage with third-party payors is the structural lever that would stabilize that rate. Whether the company delivers the positive adjusted net income it is guiding to is the milestone that would validate the growth-stage thesis, and the trajectory of cash burn and any equity raises are what dilution-sensitive holders will track. The next earnings report is the event that shows whether reimbursement is stabilizing and whether the profitability target remains in reach.

Peer Cohorts (Per Segment, With Filing Citations)

GeneDx (reported)

• NTRA (NATERA, INC.)
• FY2025 10-K: …our competitors. We rely on internal and third-party data centers and platforms to host our laboratory and cloud-based software, and any interruptions of service or failures may impair our operations and harm our business. We currently maintain a data center at our laboratory facilities in San Carlos, California. In…
• FY2025 10-K: …validity of the ‘035 Patent, which proceeding was terminated in October 2024. Pursuant to the terms of a partial settlement of the case, the District Court entered a permanent injunction against NeoGenomics, and it has withdrawn its RaDaR test from the market. The case remains pending with respect to an updated…
• GH (GUARDANT HEALTH, INC.)
• FY2025 10-K: …utility and health economics from use of our tests to patients, physicians and payers; and ▪ pursuing FDA and other regulatory approval internationally of our tests to facilitate reimbursement and global market access. • Strengthen our relationships with customers by: ▪ demonstrating the utility of our products in…
• FY2025 10-K: …programs and we believe our product portfolio could address the full continuum of patient care, and has utility in both the clinical and biopharmaceutical markets. Therapy Selection Guardant360 CDx Test We believe our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the FDA, and is the…
• VCYT (VERACYTE, INC.)
• FY2025 10-K: …medical guidelines, including from the National Institute for Health and Care Excellence in the United Kingdom and the European Society for Medical Oncology. Driving Global Growth with Distributed IVD Tests Once we have developed robust clinical evidence and physician adoption of our tests in the United States, we…
• FY2025 10-K: …our products in new markets outside of the United States and Europe. Adverse actions in any of these areas could significantly increase our expenses and limit our revenue and profitability. If we are unable to compete successfully, we may be unable to increase or sustain our revenue and profitability. We operate in a…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.